Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-24
2010-06-01
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000, C548S250000, C548S254000, C548S490000
Reexamination Certificate
active
07728023
ABSTRACT:
The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and/or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.
REFERENCES:
patent: 5229413 (1993-07-01), Gray et al.
patent: 5530019 (1996-06-01), Okada et al.
patent: 5968745 (1999-10-01), Thorp et al.
patent: 6608059 (2003-08-01), Daines et al.
patent: 6833387 (2004-12-01), Faull et al.
patent: 2003/0207915 (2003-11-01), Cheng et al.
patent: 2005/0004114 (2005-01-01), Whitehouse et al.
patent: 2005/0159474 (2005-07-01), Arnould
patent: 2006/0194797 (2006-08-01), Takeuchi
patent: 03-047123 (1991-02-01), None
patent: 7-507574 (1995-08-01), None
patent: 10-512291 (1998-11-01), None
patent: 2002-536362 (2002-10-01), None
patent: 02/00646 (2002-01-01), None
patent: 03/074051 (2003-09-01), None
patent: 03/082271 (2003-10-01), None
patent: 2004/099192 (2004-11-01), None
patent: 2005/021518 (2005-03-01), None
Stella, Valentino J, Expert Opinion of Therapeutic Patents, Prodrugs as therapeutics, 2004 14(3): 277-280.
Wolff et al. (Burger's Medicinal Chemistry, 5th Ed., vol. 1, pp. 975-977, 1994).
Testa, Bernard, Biochemical Pharmacology, Prodrug Research: futile or fertile? 68 (2004) 2097-2106.
Ettmayer, Peter, Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, 47(10) (2004) 2394-2404.
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
M. Julia et al., Research in the Indole Series VII. The Cyclization of α-Arylaminoketones, Chemical Abstracts, vol. 58, Abstract No. 12495c, 1963.
R. A. Daines et al., “First X-Ray Cocrystal Structure of a Bacterial FabH Condensing Enzyme and a Small Molecule Inhibitor Achieved using Rational Design and Homology Modeling”, Journal of Medicinal Chemistry, vol. 46, No. 1, pp. 5-8, 2003.
S. B. Rajur et al., “Synthesis of 1,2,3,4-Tetrahydropyrazino-[1,2-α]indoles and ethyl 1-(2-amino-ethyl)indole-2-carboxylates”, Indian Journal of Chemistry, vol. 28B, No. 12, pp. 1065-1068, Dec. 1989.
L. D. Basanagoudar et al., “Synthesis of 10-phenyl-1,2,3,4-tetrahydropyrazino[1,2-α]indoles and ethyl 1-(2-aminoethyl)-3-phenylindole-2-carboxylates”, Indian Journal of Chemistry, vol. 30b, No. 11, pp. 1014-1017, Nov. 1991.
F. G. Salituro et al., “3-(2-Carboxyindol-3-yl)propionic Acid-Based Antagonists of the N-Methyl-D-Aspartic Acid Receptor Associated Glycine Binding Site”, J. Med. Chem., vol. 35, No. 10, pp. 1791-1799, 1992.
R. D. Fabio et al., “Substituted Indole-2-Carboxylates as in Vivo Potent Antagonists Acting as the Strychnine-Insensitive Glycine Binding Site”, J. Med Chem., vol. 40, No. 6, pp. 841-850, 1997.
T. Heinrich et al., “A New Synthesis of Indole 5-Carboxylic Acids and 6-Hydroxy-Indole-5-Carboxylic Acids in the Preparation of an o-Hydroxylated Metabolite of Vilazodone”, Bioorganic & Medical Chemistry Letters, vol. 14, No. 10, pp. 2681-2684, 2004.
Fujita Manabu
Nakayama Yoshisuke
Takeuchi Jun
Ono Pharmaceutical Co. Ltd.
Saeed Kamal A
Shterengarts Samantha L
Wenderoth Lind & Ponack, LLP.
LandOfFree
Indole compound and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole compound and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole compound and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178653